Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
NCT06938282Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4642 in pancreatic cancer (PC), sponsored by Zhongshan Hospital, Fudan University. Started Jun 2025; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06938282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938282.